A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy

(2018) Yared Hailemichael et al.   JOURNAL OF CLINICAL INVESTIGATION

Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer

(2017) Shikhar Mehrotra et al.   Journal of Hematology & Oncology

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

(2017) Ugur Sahin et al.   NATURE

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope

(2016) P. Baumgaertner et al.   OncoImmunology

Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival

(2015) C. M. Reed et al.   CLINICAL CANCER RESEARCH

A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

(2015) B. M. Carreno et al.   SCIENCE

Vaccines, Adjuvants, and Dendritic Cell Activators—Current Status and Future Challenges

(2015) Joseph Obeid et al.   SEMINARS IN ONCOLOGY

An optimized peptide vaccine strategy capable of inducing multivalent CD8+T cell responses with potent antitumor effects

(2015) Hyun-Il Cho et al.   OncoImmunology

Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund’s adjuvant, with or without peptide

(2013) Elise P. Salerno et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)

(2013) C. L. Slingluff et al.   CLINICAL CANCER RESEARCH

Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

(2013) Yared Hailemichael et al.   NATURE MEDICINE

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

(2012) P. Sabbatini et al.   CLINICAL CANCER RESEARCH

Dose-finding design for multi-drug combinations

(2011) Nolan A Wages et al.   Clinical Trials

Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine

(2011) Craig L. Slingluff et al.   JOURNAL OF CLINICAL ONCOLOGY

Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis

(2010) Jochen T Schaefer et al.   Journal of Translational Medicine

Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates

(2010) Kavita Tewari et al.   VACCINE

Optimized Peptide Vaccines Eliciting Extensive CD8 T-Cell Responses with Therapeutic Antitumor Effects

(2009) H.-I. Cho et al.   CANCER RESEARCH

Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

(2009) C. L. Slingluff et al.   CLINICAL CANCER RESEARCH

Evaluation of the Sentinel Immunized Node for Immune Monitoring of Cancer Vaccines

(2008) Craig L. Slingluff et al.   ANNALS OF SURGICAL ONCOLOGY

Differential effects of age on circulating and splenic leukocyte populations in C57BL/6 and BALB/c male mice

(2008) Lesya M Pinchuk et al.   Immunity & Ageing